Gewinn- und Verlustrechnung von CRISPR Therapeutics AG

Crisper Therapeutics (CSPR), Arista Networks (ANET), and Nebius (NBIS) are all seeing outsized intraday moves today

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company's Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics has two important data readouts coming up soon. In both cases, it'll need to demonstrate that its candidate is more effective than the alternatives in development and on the market.

Septerna (NASDAQ: SEPN - Get Free Report) and CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends. Earnings and Valuation This table compares Septerna and CRISPR

CRISPR Therapeutics AG (NASDAQ: CRSP - Get Free Report) General Counsel James Kasinger sold 10,400 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $60.24, for a total transaction of $626,496.00. Following the transaction, the general counsel directly owned 94,784 shares of

CRISPR Therapeutics AG (CRSP) reached $54.23 at the closing of the latest trading day, reflecting a -2.64% change compared to its last close.

CRISPR Therapeutics AG remains a long-term Buy, anchored by Casgevy's commercial success and management's execution in ex vivo gene editing. Casgevy's Q2 sales grew 78% sequentially, reinforcing its blockbuster potential despite market skepticism and slow initial uptake. Anthropic's AI-driven gene editing discovery introduces potential competitive and funding risks, but clinical impact appears distant.

CRISPR Therapeutics is transitioning into a commercial-stage company with its pioneering gene-editing treatment, CASGEVY. Vertex Pharmaceuticals maintains a dominant, highly profitable position in the global cystic fibrosis market.